The development and regulatory approval of chimeric antigen receptor T cell (CAR-T)
therapies targeting the B-lineage surface antigen CD19 represents a major milestone in
cancer immunotherapy. This treatment also results in depletion of normal CD19+ B cells and
is associated with hypogammaglobulinemia. These on-target, off-tumor toxicities may result
in an increased risk for infection, particularly for encapsulated bacteria. Data regarding the
efficacy and cost-effectiveness of prophylactic IgG replacement in CD19-targeted CAR-T cell …